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Neuregulin/erbB signaling is critically required for survival and proliferation of Schwann cells as well as for establishing correct myelin
thickness of peripheral nerves during development. In this study, we investigated whether erbB2 signaling in Schwann cells is also
essential for themaintenance of myelinated peripheral nerves and for Schwann cell proliferation and survival after nerve injury. To this
end, we used inducible Cre-loxP technology using a PLP-CreERT2 allele to ablate erbB2 in adult Schwann cells. ErbB2 expression was
markedly reduced after induction of erbB2 gene disruptionwith no apparent effect on themaintenance of already establishedmyelinated
peripheral nerves. In contrast to development, Schwann cell proliferation and survival were not impaired inmutant animals after nerve
injury, despite reduced levels of MAPK-P (phosphorylated mitogen-activated protein kinase) and cyclin D1. ErbB1 and erbB4 do not
compensate for the loss of erbB2. We conclude that adult Schwann cells do not require major neuregulin signaling through erbB2 for
proliferation and survival after nerve injury, in contrast to development and in cell culture.
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Introduction
Lesions of peripheral nerves initiate a sequence of cellular
changes distal to the injury known as Wallerian degeneration
(Griffin and Hoffman, 1993; Scherer and Salzer, 2001). They in-
clude axonal degeneration, myelin breakdown, and de-
differentiation and proliferation of Schwann cells. Themolecular
phenotype of “denervated” Schwann cells in axotomized nerves
is similar to immature Schwann cells in developing nerves (Jessen
and Mirsky, 2005; Sherman and Brophy, 2005). However, con-
trol of proliferation differs. Schwann cell proliferation is inde-
pendent of cyclin D1 in development, but injury-induced prolif-
eration is strongly impaired in the absence of cyclin D1 (Kim et
al., 2000; Atanasoski et al., 2001). Furthermore, the cell cycle
inhibitor p21 regulates Schwann cell proliferation in develop-
ment and after injury by different mechanisms (Atanasoski et al.,
2006). Characterizing the molecular signals that control the re-
sponse of Schwann cells to injury has implications for our under-
standing of disease mechanisms in inherited and acquired neu-
ropathies (Suter and Scherer, 2003; Berger and Schaumburg,
1995).
Schwann cells express erbB2 and erbB3 forming functional
heterodimeric receptors for neuregulins (Cohen et al., 1992; Jin et
al., 1993; Ho et al., 1995; Levi et al., 1995; Grinspan et al., 1996;
Carroll et al., 1997; Vartanian et al., 1997). ErbB2 and erbB3 are
obligate heterodimers, because erbB2 alone does not efficiently
bind neuregulins and erbB3 has no kinase activity (Sliwkowski et
al., 1994). In development, neuregulin-1 isoforms have potent
effects on differentiation, survival, and proliferation of Schwann
cells (Shah et al., 1994; Dong et al., 1995; Morrissey et al., 1995;
Grinspan et al., 1996; Trachtenberg and Thompson, 1996). Ani-
mals deficient in erbB2, erbB3, or the PNS-enriched isoform of
neuregulin-1, show reduced numbers of precursors and imma-
ture Schwann cells (Riethmacher et al., 1997; Britsch et al., 1998;
Morris et al., 1999; Woldeyesus et al., 1999; Wolpowitz et al.,
2000). Lowered expression of the neuronal neuregulin-1, or con-
ditional ablation of erbB2 in late Schwann cell development,
causes defects in postnatal Schwann cell differentiation and the
formation of abnormally thinmyelin sheaths (Garratt et al., 2000;
Chan et al., 2004; Michailov et al., 2004; Taveggia et al., 2005).
Conversely, overexpression of axonal neuregulin-1 in transgenic
animals induces hypermyelination (Michailov et al., 2004).
We hypothesized that erbB2/erbB3 receptor signaling plays
also an active role in proliferation control of adult Schwann cells
after nerve injury. Schwann cell proliferation inWallerian degen-
eration follows a predictable time course (Bradley and Asbury,
1970) and the expression of neuregulin and the tyrosine receptors
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erbB2 and erbB3 is coordinately induced (Cohen et al., 1992;
Carroll et al., 1997; Kwon et al., 1997), strongly implicating this
pathway in Schwann cell mitogenesis after axotomy. We tested
this hypothesis with a rigorous genetic approach by deleting
erbB2 specifically in Schwann cells of adult mice. Loss of erbB2 in
adult myelinating Schwann cells did not influence the mainte-
nance of myelinated peripheral nerves. Furthermore, in contrast
to our expectations (Carroll et al., 1997; Kwon et al., 1997; Guer-
tin et al., 2005), lack of erbB2hadnodetectable effect on Schwann
cell proliferation after nerve injury. We conclude that the signal-
ing pathways that regulate proliferation in Schwann cells after
nerve injury are fundamentally different from those identified in
development and in culture.
Materials andMethods
Animals. Hemizygous PLP-CreERT2 mice (Leone et al., 2003) and ho-
mozygous erbB2 flox mice (Garratt et al., 2000) have been described pre-
viously. The erbB2wt/lacZ mice used in this study carry an allele that
encodes a nonfunctional ErbB2-galactosidase fusion protein lacking the
tyrosine kinase domain (Britsch et al., 1998). Hemizygous PLP-CreERT2
mice were crossed with erbB2wt/lacZ animals to obtain PLP-CreERT2
erbB2wt/lacZ double transgenic mice. PLP-CreERT2 erbB2wt/lacZ animals
were then bred with homozygous erbB2 flox mice (erbB2 flox/flox) to ob-
tain control PLP-CreERT2 erbB2wt/flox and experimental PLP-CreERT2
erbB2 lacZ/flox mice. The resulting genotypes from this cross were as fol-
lows: PLP-CreERT2 erbB2 lacZ/flox (one of four;
the experimental group), PLP-CreERT2
erbB2wt/flox (one of four; the control group),
erbB2 lacZ/flox (one of four), or erbB2wt/flox (one
of four). The phenotypes were analyzed on a
C57BL/6/129 hybrid background. Tail-derived
DNA was analyzed by PCR to identify PLP-
CreERT2-positivemice (Leone et al., 2003) and
to distinguish erbB2 wild-type and lacZ alleles
(Britsch et al., 1998). Primers used for detecting
PLP-CreERT2 alleles were as follows: 5-CAC
TCTGTGCTTGGTAACATGG, and 5-TGG
GAT CCG CCG CAT AAC C (94°C for 2 min,
35 times at 94°C for 45 s, 53°C for 30 s, and 72°C
for 1 min, followed by a final extension at 72°C
for 5 min). Primers used for detecting lacZ al-
leles were as follows: 5-CCA CCC TCT CGC
TCC AGA TGG TGG A, and 5-CGG GCC
TCT TCG CTA TTA CGG GAG C (94°C for 2
min, 35 times at 94°C for 45 s, and 72°C for 90 s,
followed by a final extension at 72°C for 5min).
To obtain the recombined erbB2 allele, con-
trol and mutant animals received daily intra-
peritoneal injections of 2 mg of tamoxifen
(TM) for 5 consecutive days. Sciatic nerves
were injured 10 d and 10 weeks after the last
injection, respectively. For the myelin mainte-
nance experiments, sciatic nerves were col-
lected 2months after the last injection. Primers
used for detecting the erbB2 flox allele were as
follows: primer1, CTT CGT ATA ATG TAT
GCT ATA CGA AGT TAT, and primer2, GCA
GGG CAA TAT TTG TGT CCT T (94°C for 2
min, 35 times at 94°C for 45 s, 57°C for 30 s, and
72°C for 1 min, followed by a final extension at
72°C for 5min); for the erbB2 allele: primer 3,
AGT GCC TCA TGT GTG CAG TGA GGA C,
and primer 4, TGA GTT ACA GAC CAA GCC
GCT CGA G (94°C for 2 min, 35 times at 94°C
for 45 s, 53°C for 30 s, and 72°C for 1 min,
followed by a final extension at 72°C for 5min).
Genomic DNA from sciatic nerves was pre-
pared as described previously (Garratt et al.,
2000). The perineurium was stripped from sciatic nerves to minimize
contamination by surrounding tissue.
Sciatic nerve transection. The right sciatic nerve of anesthetized mice
(100mg/kg Ketaminol; 5 mg/kg Narcoxyl, i.p.) was exposed at the sciatic
notch. The nerve was transected and the two nerve stumps diverted to
prevent axonal regeneration into the distal nerve stump. The distal nerve
stumps were recovered 4 or 12 d after transection. Contralateral nerves
were used as unlesioned control samples.
Immunofluorescence microscopy. Mice were injected intraperitoneally
with bromodeoxyuridine (BrdU) (100 g/g body weight) 2 and 1 h be-
fore killing. Nerves were fixed for 30 min in freshly prepared 4% para-
formaldehyde (in PBS), washed in PBS, incubated in 30% sucrose in PBS
overnight at 4°C, and embedded in OTC (Miles, Kankakee, IL). Five-
micrometer-thick longitudinal sections were cut at20°C andmounted
on SuperFrost/Plus glass slides (Faust, Schaffhausen, Switzerland) and
stored at 20°C. Sections were blocked for 1 h in PBS containing 10%
goat serum, 1%BSA, and 0.3%TritonX-100, and incubatedwith a rabbit
antiserum against S100 (1:300; DakoCytomation, Carpinteria, CA) for
16 h at 4°C. Slideswere rinsed in PBS and incubatedwithCy3-conjugated
goat anti-rabbit secondary antibody (1:200; Jackson ImmunoResearch,
West Grove, PA) for 1 h at room temperature (RT). Sections were rinsed
in PBS, and then fixed in 4% paraformaldehyde for 10min on ice, rinsed
in PBS, incubated inmethanol for 10min on ice, rinsed in PBS, incubated
in 1 M HCl at 60°C for 7 min, rinsed in PBS, incubated with biotinylated
antibody against BrdU (1:10; Caltag Laboratories, South San Francisco,
CA) for 1 h at 37°C, rinsed, and incubatedwith streptavidin-FITC (1:400;
Figure 1. The floxed erbB2 locus is efficiently recombined by the Cre recombinase in Schwann cells of adult peripheral nerves.
A, Schematic representation of the erbB2 flox allele with two loxP sites (triangle) flanking three exons (top). The erbB2 allele
(bottom) is obtained after Cre-induced recombination of erbB2 flox. The arrows indicate primers used for PCR analysis. Exons are
indicated by boxes and lettered (Garratt et al., 2000). B, PCR detecting the recombined erbB2 allele in genomic DNA from adult
sciatic nerves of three untreated (lanes 1–3) and three TM-treated (lanes 4–6) mutant animals (PLP-CreERT2 erbB2 lacZ/flox). C,
Semiquantitative PCR detecting the non-recombined erbB2 flox allele in genomic DNA from adult sciatic nerves of three untreated
(lanes 1–3) and three TM-treated (lanes 4–6) mutant animals (PLP-CreERT2 erbB2 lacZ/flox). GAPDH serves as internal control. D,
Western blot analysis of pooled lysates prepared from sciatic nerves of control (con) andmutant (mut) mice. Control nerves were
from three PLP-CreERT2 erbB2wt/flox;mutant nerveswere from three PLP-CreERT2 erbB2 lacZ/floxmice.Mice had been treatedwith
TM for 5 consecutive days at the age of 10weeks and analyzed 2months later. Themembranewas probedwith antibodies specific
for erbB2 and-actin. Note that erbB2 is undetectable in mutant nerves.
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Jackson ImmunoResearch) for 1 h at RT. Controls with secondary
antibodies only showed negligible stainings. Sections were mounted
in AF1 (Citifluor, Canterbury, UK) supplemented with 4,6-
diamidino-2-phenylindole (1:1000; Roche, Basel, Switzerland). Im-
munoreactivity was visualized by epifluorescence microscopy and
documented using a Hamamatsu (Hamamatsu City, Japan) Color
Chilled 3CCD camera. Images were processed with Adobe Photoshop
7.0 for Macintosh.
Statistical analysis. Three animals per genotype were analyzed, and the
individual who counted was blinded to the genotype of the mice. BrdU-
positive cells were counted in two adjacent 40 objective fields, each
covering an area of 0.25 mm2,2.5–3.0 mm distal to the site of transec-
tion. To avoid possible differences in cell size or sampling biases, six
random sections from different levels within a nerve were examined. A
total of 1000 S100-positive cells per nerve and mouse have been ana-
lyzed. The percentage of S100/BrdU-positive cells was determined
(mean  SD) and the values transformed with arcsin[sqrt(percentage/
100)]. The transformed values were compared using the two-tailed un-
paired Student’s t test.
Western blotting. Sciatic nerve tissue was dissected from killed mice,
frozen in liquid nitrogen, pulverizedwith a chilledmortar and pestle, and
dissolved in SDS gel sample buffer (Atanasoski et al., 2004). Nerves of at
least three mice per genotype were pooled, and two pools were analyzed
in duplicate. Proteins were electrophoresed on 5% SDS-polyacrylamide
gels, transferred onto polyvinylidene difluoride membrane, and immu-
noblotted with antibodies against epidermal growth factor receptor
(EGFR)/erbB1 (NeoMarkers, Fremont, CA) at 1:1500 dilution, erbB2
(Santa Cruz Biotechnology, Santa Cruz, CA) at 1:100 dilution, erbB3
(Santa Cruz Biotechnology) at 1:100 dilution, erbB4 (a kind gift from
Cary Lai, The Scripps Research Institute, La Jolla, CA) at 1:5000 dilution,
mitogen-activated protein kinase (MAPK) (Cell Signaling, Beverly, MA)
at 1:1000 dilution, phosphorylatedMAPK (MAPK-P) (Cell Signaling) at
1:1000 dilution, cyclin D1 (Santa Cruz Biotechnology) at 1:100 dilution,
and -actin (Sigma, St. Louis, MO) at 1:500 dilution. After incubating
with goat anti-rabbit horseradish peroxidase- (Santa Cruz Biotechnol-
ogy) or goat anti-mouse  chain alkaline phosphatase-conjugated sec-
ondary antibodies (Southern Biotechnology, Birmingham, AL), the im-
munoreactive bands were visualized byWestern Lightning (PerkinElmer
Life Sciences, Wellesley, MA) or CDP-Star (Roche), respectively. The
blots were quantified using the ImageJ software (http://rsb.info.nih.gov/
ij/), normalizing the individual lanes to the -actin signal.
Light microscopy. Mice were killed, and sciatic nerves were removed
and placed in fixative (3% glutaraldehyde on 0.1 M phosphate buffer, pH
7.4) overnight at 4°C. The samples were washed twice in 0.1 M phosphate
buffer, pH 7.4, placed in 2%osmium tetroxide in 0.1 M phosphate buffer,
rinsed in water, dehydrated with successively increasing percentages of
ethanol (25, 35, 50, 70, 80, 95, and 100%) followed by propylene oxide,
infiltrated in 50 and 75%epoxy in propylene oxide, and then 100%epoxy
overnight, embedded in fresh epoxy, and hardened in a 60°C oven. Semi-
thin sections (500 nm) were stained with 1% toluidine blue and photo-
graphed on a Leica (Nussloch, Germany) DMR microscope using a
cooled Hamamatsu camera. Images were scanned and manipulated in
Adobe Photoshop. The observer (S. S. Scherer) was blinded to the geno-
type of the mice.
g ratio determinations. Semithin sections of a peroneal nerve from each
of three control (Cre; erbB2 wt/flox) and three mutant (Cre; erbB2 lacZ/
flox) mice were imaged on a Leica DM microscope with a 100 oil
immersion lens. For each nerve, one of the captured images was analyzed
withOpenLab software, using aWacom Intuos 3 (9 12) digital tablet to
trace all of the myelinated axons in the image, excluding those with
regions of uncompactedmyelin. For eachmyelinated axon, the diameter
of the axon and the outer diameter of the compact myelin sheath were
traced. These data were transferred to aMicrosoft (Redmond,WA) Excel
spreadsheet and used to calculate a g ratio (the axon diameter/total di-
ameter) for each axon. The g ratios of the control andmutant nerves were
plotted, and a one-tailed Student’s t test was performed. No statistical
difference was found ( p 0.11).
Results
Efficient ablation of erbB2 in adult Schwann cells of
peripheral nerves
In this study, we have used a TM-inducible variant of the Cre
recombinase (CreERT2) (Metzger et al., 1995; Feil et al., 1996) as
a transgene under the control of mouse proteolipid protein (Plp)
gene regulatory elements. This transgene can be specifically acti-
vated in Schwann cells in vivo to allow loxP site-mediated recom-
bination (Leone et al., 2003). PLP-CreERT2 animals were crossed
with erbB2wt/lacZ mice (the erbB2 lacZ allele represents a null al-
lele). Resulting PLP-CreERT2 erbB2wt/lacZ animals were mated
with mice homozygous for the conditional erbB2 allele
(erbB2 flox/flox) in which loxP sites flank exons encoding crucial
parts of the extracellular domainof the receptor (Fig. 1A) (Garratt et
al., 2000). This strategy yielded PLP-CreERT2 erbB2flox/lacZ mice
(experimental/mutant group) and PLP-CreERT2 erbB2 flox/wt
mice (control group).
Based on our previous optimization studies (Leone et al.,
2003), 10-week-oldmice received daily intraperitoneal injections
of 2 mg of TM for 5 consecutive days to activate the Cre-ERT2
fusion protein and to delete the floxed erbB2 allele (erbB2),
present in both control and mutant mice (Fig. 1A). Genomic
DNA from mutant sciatic nerves of treated mice was analyzed 2
months after the last TM injection to verify genomic deletion at
the erbB2 locus (Fig. 1B,C). A 500 bp product corresponding to
the deleted erbB2 allele (erbB2) appeared exclusively in the PCR
analysis of sciatic nerve DNA from individual TM-treated mu-
tant animals (Fig. 1B, lanes 4–6) but not in theDNAof untreated
Figure 2. Myelinated peripheral nerves are maintained in the absence of erbB2. These are
images of transverse semithin sections of adult mouse nerves stained with toluidine blue. The
tibial, peroneal, and sural branches of the sciatic nerve are shown for one control and one
mutant mouse, 10 weeks after TM induction. Scale bar, 10m.
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mutant mice (Fig. 1B, lanes 1–3). Conversely, the amount of a
200 bp product, corresponding to the erbB2 flox allele, was mark-
edly reduced after TM treatment of mutant animals (Fig. 1C,
compare lanes 1–3 with lanes 4–6). Western blot analysis using
nerve lysates from three pooled animals per genotype revealed
that protein levels of erbB2 were not detectable in mutant com-
pared with control nerves, 2 months after the last TM injection
(Fig. 1D). We conclude that we have achieved highly efficient
induced recombination of the floxed erbB2 gene, leading to
strongly reduced levels of erbB2 protein in adult sciatic nerves.
Myelinated peripheral nerves are maintained and not
detectably altered after erbB2 ablation in adult Schwann cells
Next, we examined whether loss of erbB2 in adult Schwann cells
affects themaintenance ofmyelinated peripheral nerves. Figure 2
shows semithin cross sections of PLP-CreERT2 erbB2flox/wt and
PLP-CreERT2 erbB2flox/lacZ adult sciatic nerves 2 months after
TM treatment. An observer who was blinded to the genotypes of
the mice could not detect differences in the structure or in the
degree of myelination when examining the tibial, peroneal, and
sural branches of three mutants and three
control mice; all looked normal. Figure 2
shows examples from amutant and a con-
trol mouse. To corroborate these observa-
tions, the g ratios of the control and mu-
tant nerves were determined, and no
significant differences were found (sup-
plemental figure, available at www.
jneurosci.org as supplemental material).
These findings indicate that Schwann cell-
expressed erbB2 is not required for the
maintenance of myelinated axons in adult
peripheral nerves.
Schwann cell proliferation inWallerian
degeneration is not affected in adult
erbB2-conditional null nerves
The finding that erbB2-deficient nerves
appeared to be normal allowed us to ex-
amine the specific potential requirement
for neuregulin/erbB signaling in prolifer-
ation and survival of adult Schwann cells
in Wallerian degeneration. For this analy-
sis, we examined longitudinal sections of
the distal nerve stump at 4 d posttransec-
tion (4dpT), when Schwann cell prolifer-
ation is highest (Bradley and Asbury,
1970) and 12dpT, when erbB2 protein lev-
els are high (Carroll et al., 1997; Kwon et
al., 1997). We induced erbB2 ablation
with TM in three control and three mu-
tantmice, and transected one sciatic nerve
10 d after the last TM injection.Mitotically
active Schwann cells were labeled by puls-
ing with BrdU at 4dpT or 12dpT. No
BrdU-labeled Schwann cells were seen in
uninjured controls or mutant nerves,
whereas we found numerous BrdU-
labeled cells in lesioned nerves of both ge-
notypes 4dpT (Fig. 3A). Double labeling
with the marker protein S100 demon-
strated that the BrdU-positive cells were
Schwann cells. We counted at least 1000
Schwann cells per mouse and determined that, at 4dpT and
12dpT, there were no significant differences in BrdU-positive
cells between control and mutant nerves (Fig. 3B).
Because erbB2 signaling is also required for cell survival dur-
ing development (Jessen et al., 1994; Grinspan et al., 1996; Gar-
ratt et al., 2000), we tested whether erbB2 ablation in adult
Schwann cells causes increased apoptosis. No apoptotic cells were
detected in control or mutant nerves, neither before nor after
axotomy (data not shown).
To corroborate our results, we also ablated erbB2 using a sec-
ond mouse line expressing CreERT2 under the control of the
Schwann cell-specific Mpz/P0 promoter and regulatory regions
of the human connexin32 gene (P0Cx-CreERT2) (Leone et al.,
2003). Again, we found no differences in either the proliferation
or the apoptosis of Schwann cells after axotomy between erbB2-
deficient versus control mice (data not shown).
To determine the efficiency of erbB2 protein loss at 4dpT,
Western blots of nerve lysates from two pools of four pooled
animals per genotype were probed for erbB2, erbB3, and -actin
(Fig. 4A). The level of erbB2 in mutant animals was strongly
Figure 3. ErbB2-mediated signaling is not required for injury-induced proliferation of Schwann cells.A, Images of longitudinal
sections of uninjured (a, b) and the distal stumps of injured (4dpT; c, d) sciatic nerves, double-labeled with an anti-BrdU mono-
clonal antibody (green) and a rabbit antiserum against the Schwann cell marker S100 (red). Nerves were taken from control (a,
c) and mutant (b, d) animals; control nerves were from PLP-CreERT2 erbB2wt/flox; mutant nerves were from PLP-CreERT2
erbB2 lacZ/floxmice. Allmice had been treatedwith TM for 5 consecutive days at 10weeks of age. Surgerywas performed 10 d after
the last TM injection. Note that thenumber of BrdU-positive nuclei is similar inmutants and control animals at 4dpT. Contralateral,
unlesionednerves containno labeled cells. Scale bar, 40m.B, Quantitative analysis of cell proliferation in control (con) (graybar)
andmutant (mut) (black bar) sciatic nerves 4dpT and12dpT. Data aremean values obtained from three animals per timepoint and
genotype. There is no significant difference between the control and mutant nerves by Student’s t test. Error bars indicate SD.
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reduced compared with control nerves in
lesioned and unlesioned nerves (Fig.
4A,B).Note that, as expected (Cohen et al.
1992; Carroll et al. 1997), the erbB2 level
in lesioned control nerves was higher than
in unlesioned control nerves (Fig. 4A,B).
ErbB3 levels were not affected by the abla-
tion of erbB2, neither in unlesioned nor
lesioned nerves (Fig. 4A). Thus, condi-
tional disruption of the erbB2 gene in
adult Schwann cells results in drastically
reduced erbB2 levels at 4dpT without sig-
nificant effects on cell proliferation or sur-
vival during early and late Wallerian
degeneration.
We next examined the possibility that
the residual erbB2 protein expressed in in-
jured nerves 10–14 d after the last TM in-
jection (Fig. 4A) might account for the
unchanged proliferative response of
Schwann cells in mutant mice (Fig. 3).
Based on ourmyelinmaintenance studies,
we waited 10weeks after the last TM injec-
tion to achieve nondetectable levels of
erbB2 in Schwann cells (Fig. 1D) before
injuring three control and three mutant
sciatic nerves. Again, there were no signif-
icant differences in BrdU-positive cells be-
tween control and mutant nerves (data
not shown). These results corroborate our
finding, that erbB2 signaling is largely dis-
pensable for proliferation after nerve
axotomy.
EGFR/erbB1 and erbB4 do not
compensate for the loss of erbB2
To test the possibility that other erbB re-
ceptor family members compensate for
the loss of erbB2, we analyzed the expres-
sion of EGFR/erbB1 (Ullrich et al., 1984;
Carpenter, 1987) and erbB4 (Lai and
Lemke, 1991; Plowman et al., 1993) in
mutant and control groups of lesioned
and unlesioned sciatic nerves by Western
blotting (Fig. 4C). EGFR1/erbB1 and
erbB4 were not detectably expressed in normal (Cohen et al.,
1992; Levi et al., 1995; Grinspan et al., 1996) and mutant sciatic
nerves, regardless of lesions, indicating that there was no major
compensation by these related receptors.
Ablation of erbB2 in adult Schwann cells alters the levels of
active MAPK and cyclin D1
Puzzled by the unexpected findings, we examinedwhether down-
stream signaling molecules of the neuregulin/erbB pathway are
affected by the erbB2 mutation. Nerve lysates of four mice per
genotype were pooled and two pools were analyzed for the ex-
pression of MAPK-P, total MAPK, and -actin (Fig. 5A), and
cyclin D1 and -actin (Fig. 5C). MAPK-P levels were normalized
to total levels of MAPK (Fig. 5B). As expected, the level of
MAPK-P in lesioned nerves 4dpT was higher than that in unle-
sioned, contralateral nerves, in which Schwann cells are not pro-
liferating (Fig. 5A,B). Interestingly, MAPK-P levels were signifi-
cantly reduced in mutant compared with control nerves 4dpT
(Fig. 5A,B). Similarly, the amount of cyclin D1 in mutant mice
was reduced compared with control nerves (Fig. 5C,D). We con-
clude that downstream signalingmolecules of the erbB2 pathway
are affected after ablation of erbB2 without apparent conse-
quences for the proliferation or survival of Schwann cells during
Wallerian degeneration.
Discussion
Neuregulin/erbB signaling is critically involved in several funda-
mentally important aspects of peripheral nerve development. In
this study, we focused specifically on a potential role of this im-
portant signaling pathway in the regulation of adult Schwann cell
proliferation after nerve injury. By disrupting this pathway in
peripheral nerves in a spatially and temporally controlledmanner
in vivo, we were able to show that major neuregulin signaling
through erbB2 is not an absolute requirement for the regulation
of injury-induced Schwann cell proliferation. Furthermore, we
found that erbB2 function is mostly dispensable for the mainte-
Figure 4. A, Western blot analysis of lysates prepared fromuninjured nerves (lanes 1 and 2) and from adult sciatic nerves 4dpT
(lanes 3 and 4). Control (con) nerves were from PLP-CreERT2 erbB2wt/flox, and mutant (mut) nerves were from PLP-CreERT2
erbB2 lacZ/flox mice. All mice had been treated with TM for 5 consecutive days at 10 weeks of age, and surgery was performed 10 d
after the last TM injection. Membranes were probed with antibodies specific for erbB2, erbB3, and -actin. B, Quantitative
analysis relative to-actin signals. The correcteddensitometry data fromeachgroupwere compared, arbitrarily setting the erbB2
signal for unlesioned control adult nerves to 1.0. Nerves of fourmice per genotypewere pooled and two poolswere analyzed (Exp.
1 and2).C, ErbB4 and erbB1donot compensate for the loss of erbB2.Western blot analysis of uninjured (lanes 1 and2) and injured
sciatic nerves (4dpT; lanes 3 and 4), from adult control and mutant mice as described in Figure 3A. Membrane was probed with
antibodies specific for erbB4, erbB1, and-actin. Protein extract of cultured oligodendrocytes (OLs) expressing both erbB4 and
erbB1 was used as a positive control (lane 5).
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nance of myelinated peripheral nerves. These combined findings
support our previous results (Atanasoski et al., 2002, 2006) that
the molecular control and requirements for proper Schwann cell
function differ fundamentally during development and after
nerve damage.
We have demonstrated previously that the TM-induced re-
combination efficiency in Schwann cells of PLP-CreERT2 ani-
mals, crossed with mice carrying the Rosa26-LacZ reporter, is
80% (Leone et al., 2003). Because recombination frequencies
can vary between different alleles carrying loxP sites (Vooijs et al.,
2001), it was important to determine the efficiency of gene abla-
tion in sciatic nerves after TM-induced recombination at another
locus. In the present study, we observed almost complete recom-
bination at the erbB2 locus indicating high efficiency. This was
accompanied by75% reduction of erbB2 protein in uninjured
nerves 2 weeks after TM injection. Because erbB2 was only ab-
lated in Schwann cells, the remaining erbB2 expressionmay orig-
inate from contamination by surrounding tissue (Pearson and
Carroll, 2004) and blood vessels (Russell et al., 1999) (data not
shown), which continue to express erbB2. However, a slow turn-
over of erbB2 is amore likely explanation, because the amount of
erbB2 in mutants compared with controls is decreased from
25% in uninjured to 12% in injured
nerves when protein turnover is generally
accelerated because of the breakdown and
the phagocytosis of the myelin sheath. In
addition, erbB2 proteinwas not detectable
in mutant nerves 2 months after TM
administration.
Schwann cells express only erbB2 and
erbB3 but not detectable erbB1 or erbB4
(Vartanian et al., 1997) as confirmed in
this study. Unlike the other family mem-
bers, the intrinsic tyrosine kinase of erbB3
is catalytically inactive; active signaling de-
pends on heterodimer formation with
erbB1, erbB2, or erbB4 (Vartanian et al.,
1997). Thus, by ablating erbB2 in
Schwann cells, signal transduction by neu-
regulins is inhibited, unless other receptor
tyrosine family members compensate for
the loss of erbB2. However, we found no
detectable expression of erbB1 or erbB4 in
erbB2-deficient Schwann cells, so that
neuregulin signaling should have been
strongly impaired.
The question remains as to how the ob-
served differences between the require-
ments for the neuregulin/erbB signaling
system during development and after in-
jury are controlled. During the early post-
natal phase, Schwann cell survival and
proliferation is regulated, in part, by ac-
cess to axonally derived neuregulin-1
(Wolpowitz et al., 2000) and axotomy-
induced Schwann cell death during devel-
opment can be rescued by exogenous
neuregulin-1 (Grinspan et al., 1996; Tra-
chtenberg and Thompson, 1996). In adult
mice, the apoptotic response of Schwann
cells after axonal damage is limited (Grin-
span et al., 1996; Atanasoski et al., 2006),
and neuregulin isoforms are predomi-
nantly expressed by Schwann cells (Carroll et al., 1997). These
differences might account for the observed discrepancies be-
tween neuregulin/erbB functions in development and after nerve
injury. Conditional erbB2 ablation in immature Schwann cells
using a Krox20-cre allele leads to an increase of proliferating and
apoptotic cells in postnatal developing nerves (Garratt et al.,
2000).We also injured adult nerves of Krox20-cre erbB2flox mice
and, similar to the processes described during development (Gar-
ratt et al., 2000), we found increased Schwann cell proliferation
and cell death after nerve damage compared with controls (our
unpublished data). In contrast, ablating erbB2 exclusively in
adult Schwann cells of fully myelinated peripheral nerves has no
detectable effect on survival and cell division after injury. Thus,
Schwann cell responses to axotomy depend on the timing of
erbB2 ablation.
Analysis of neuregulin and erbB receptor expression in pe-
ripheral nerve undergoingWallerian degeneration demonstrated
that both ligands and receptors are not only expressed during the
proliferation period but also throughout a subsequent time of
markedly diminished Schwann cell mitogenesis (Carroll et al.,
1997). This raises the question of whether neuregulin/erbB sig-
naling plays a role in later stages of Wallerian degeneration. We
Figure 5. Lowered levels of activated MAPK and cyclin D1 in erbB2-conditional null nerves. A, Western blot analysis of pooled
uninjured (lanes 1 and2) and injured (4dpT; lanes 3 and4) sciatic nerves fromadult control andmutantmice as described in Figure
4A. Membranewas probedwith antibodies specific forMAPK-P (top), totalMAPK (middle), and-actin (bottom).B, The amount
of MAPK-P was corrected for unequal total MAPK signals. The corrected densitometry data from each group were compared,
arbitrarily setting theMAPK-P signal for unlesioned control adult nerves to 1.0. Nerves of fourmice per genotypewere pooled and
two pools were analyzed (Exp. 1 and 2). C, Western blot analysis of pooled injured sciatic nerves (4dpT) from adult control (lane 1)
andmutant (lane 2)mice. Themembranewas probedwith antibodies specific for cyclin D1 (CycD1) and-actin.D, Quantification
of the signals shows a significant decrease in cyclin D1 levels in injured mutant nerves. Nerves of four mice per genotype were
pooled, and two pools were analyzed (Exp. 1 and 2). con, Control; mut, mutant.
Atanasoski et al. • Neuregulin/erbB Signaling in Adult Schwann Cells J. Neurosci., February 15, 2006 • 26(7):2124–2131 • 2129
did not observe differences in proliferation or survival of
Schwann cells 12 d posttransection when erbB2 levels are high in
wild-type nerves. However, it remains to be determined whether
erbB2 plays a role in remyelination, similar to its function in
myelination during normal development.
Despite the finding that proliferation rates are not altered in
conditional erbB2-null nerves after injury, we observed reduced
levels of signaling molecules involved in the erbB2 pathway trig-
gering proliferation, such as phosphorylated MAPK and cyclin
D1 (Rahmatullah et al., 1998). We hypothesize that these mole-
cules were not sufficiently suppressed to abolish proliferation.
Alternatively, PI3-K (phosphatidylinositol 3-kinase), which has
been shown to promote Schwann cell proliferation (Maurel and
Salzer, 2000), might be involved in this paradigm. Furthermore,
extracellular factors other than neuregulinsmay contribute to the
regulation of Schwann cell proliferation and survival after axonal
damage and/or compensate for the loss of neuregulin/erbB func-
tion. TGF might be a candidate because it is involved in the
regulation of Schwann cell proliferation, survival, and differenti-
ation (Ridley et al., 1989; Mews andMeyer, 1993; Einheber et al.,
1995; Guenard et al., 1995; Parkinson et al., 2001; Awatramani et
al., 2002; Day et al., 2003; Atanasoski et al., 2004). It remains to be
seen whether interrupting this signaling pathway will have an
impact on proliferation of adult Schwann cells after injury. Other
mitogens that may play a role include PDGF (Hardy et al., 1992),
NT-3 (neurotrophin 3) (Funakoshi et al., 1993), and IGF (Son-
dell et al., 1997).
In summary, efficient Schwann cell-specific ablation of erbB2
in adultmice using two different CreERT2 lines has no detectable
effects on themaintenance of myelinated peripheral nerves or on
proliferation and survival of adult Schwann cells after injury.
These findings are in sharp contrast to the observed developmen-
tal deficits when erbB2 is ablated in immature Schwann cells,
strongly suggesting that the molecular control of Schwann cell
proliferation is different during development than after nerve
injury. It will be an exciting task to define the crucial signaling
pathways that regulate Schwann cell proliferation after lesion.
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